The creation of Moderna’s pharmaceutical manufacturing facility in Laval is “important” and “highly strategic,” according to the CEO of the Metropolitan Chamber of Commerce (CCMM), which anticipates significant spin-offs in a variety of Montreal and Montreal sectors. Quebec’s economy.
“It’s been easily 20 years since we made such a significant investment in an area of life sciences,” said Mr. Leblanc, who originally founded the life sciences industrial cluster in Montreal, in a 2000s interview with InVivo.
The biopharmaceutical company announced on Thursday that it has signed a purchase agreement for land in the Laval biotechnology park to build its factory, which is expected to have a production capacity of 100 million doses of vaccines per year.
The location of the plant is “ideal”, explains Moderna: It is the Cité de la Biotech, a developing industrial park in the Chomedey sector, which brings together large biopharmaceutical companies and research institutes and employs several thousand people.
“This location offers Moderna tremendous synergy opportunities through its proximity to a renowned research facility and is consistent with the needs of the project and its importance to all Quebecers and Canadians,” Moderna said in a statement Thursday.
According to Michel Leblanc, “the more we have big strategic players, as is the case in the aviation sector, it is extremely promising to have a big pharmaceutical company specializing in the manufacture of vaccines”.
Highlighting the work of ministers in Ottawa and Quebec City, Mr. Leblanc points out that in addition to the paid jobs directly linked to the plant, there are also opportunities for local suppliers of manufacturing equipment, transportation or even construction.
The land was ceded by the National Institute for Scientific Research (INRS), which runs a research center in the city, in which it has a stake.
For the mayor of Laval, Stéphane Boyer, “it is clear that the addition of an important player like Moderna to our project is a real privilege. We welcome them today with enthusiasm and will follow these files with close attention,” he said in a written statement.
INRS said it was “fortunate” to cede land to meet the needs of the future biofactory, which will specialize in making messenger RNA vaccines, a technology first spreading with the COVID-19 vaccines Has.
“There is no doubt that adding a partner of this scale will add to the impact of the Laval technology park in Quebec and Canada and energize the life sciences and health technology ecosystem,” the research organization said in an email.
Construction of the facility is scheduled to begin in 2022 and is expected to be operational by the end of 2024, subject to planning and regulatory approvals, it said.
Health Minister Christian Dubé said on Twitter: “The arrival of Moderna in Quebec is a sign of innovation in healthcare. This is important and we are very proud of it.”